Outcome of Outpatient/Ambulatory and Inpatient/Stationary SettingNCT05234242
Inguinal Hernia Treatment: Stationary/Inpatient vs. Ambulatory/Outpatient Setting - HerStAmb Study
An observational study of Outcome of Outpatient/Ambulatory and Inpatient/Stationary Setting, run by Dr. Michal Ziga at 1 site in Switzerland.
Trial summary
Since 01/2018, AVOS (ambulant vor stationär = ambulatory to stationary) regulation has been progressively implemented in hospitals across Switzerland for certain surgical procedures, including the treatment of inguinal hernias. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Outcome of Outpatient/Ambulatory and Inpatient/Stationary Setting
- What is being tested?
- inguinal hernia repair
- Type of treatment
- Surgery or procedure
- How many people
- 237 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2019to 1 Apr 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All the patients included in the study were diagnosed with the symptomatic primary unilateral inguinal hernia. They have various jobs and different lifestyles.
Who may be able to join
- Primary unilateral inguinal hernia
- Written informed consent after participants' information,
- Outpatient or inpatient treatment
Who cannot join
- Recurrent hernia
- Bilateral hernia
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Inguinal Hernia Treatment: Stationary/Inpatient vs. Ambulatory/Outpatient Setting - HerStAmb Study (Prospective Non-randomized Multicenter Comparative Study)
Since 01/2018, AVOS (ambulant vor stationär = ambulatory to stationary) regulation has been progressively implemented in hospitals across Switzerland for certain surgical procedures, including the treatment of inguinal hernias.
The aim of this prospective, non-randomized, multicenter study was to compare the outcome of outpatient/ambulatory and inpatient/stationary postoperative care by examining the re-admission rate, complication rate and quality of life in patients with primary unilateral inguinal hernia repair.
Read the detailed description
Inguinal hernia repair procedures are among the most performed surgeries worldwide, with more than 20 million people undergoing the procedure annually. Various tension or tension-free operation-techniques have been developed over the years. According to the International Guidelines developed by HerniaSurge Group in 2018, the gold standard are tension-free procedures with prosthetic material (mesh), either laparoscopic (total extraperitoneal patch (TEP), transabdominal preperitoneal patch (TAPP) or open surgery (Lichtenstein). In Switzerland, open surgery is used for 58.5% of hernias while 41.5% are operated on laparoscopically with the TEP as the first choice. Similar data is also reported in Great Britain. The development of modern anaesthesia as well as the safe techniques performed by experienced surgeons permit treatment of inguinal hernias in the outpatient setting, while the American Society of Anaesthesiologists (ASA) state that I - III class patients who have satisfactory care at home should be considered for day surgery. A crucial role in the process is played by the anaesthesiologist and surgeon who are responsible for perioperative management and the early postoperative phase. The factors in favour or against the suitability of day surgery include environmental factors (hospital, physician) as well as patient-related factors and thus a tailored approach must be considered for each patient. Outpatient treatment can only be performed in a hospital with suitable infrastructure (pre-assessment, day surgery department) and a high caseload, which usually results in the surgery being routine, with less complications occurring and a shorter procedure time. Control of postoperative pain and nausea are also very important for quick discharge. The financial support of the healthcare system also plays a significant role.
While there is a growing trend towards day surgery, considerable variations exist internationally and between hospitals at the national level. The evaluation of the French hernia register by Drissi et al showed slightly lower re-admission rate in ambulatory patients while Steger et al report a positive experience as well as acceptance of the ambulatory TEP procedure in one centre in Germany. Köckerling et al showed no significant differences in pain and recurrence rate in primary elective unilateral inguinal hernia treated in the outpatient setting. However, there are no prospective studies and data comparing outpatient/ambulatory vs. inpatient/stationary treatment setting in respect of complications, re-admission rate and patient outcome/quality of life.
Since 01/2018, AVOS (ambulant vor stationär = ambulatory to stationary) regulation has been progressively implemented in Swiss hospitals for certain procedures - inguinal hernia treatment included. AVOS regulation passed into law in 01/2019, with small modifications made to the recommendations of the European Hernia Society for hernia treatment in the outpatient setting.
Our study is the first prospective study comparing the efficiency and the effectiveness of ambulatory/outpatient and stationary/inpatient postoperative management through the investigation of the postoperative re-admission rate, complication rate and patient outcome/quality of life after the procedure in a group of patients with primary unilateral inguinal hernia.
The study was designed as a prospective non-randomized multicentre study carried out at 2 Swiss hospitals (Centre A: Triemli City Hospital, Centre B: Cantonal Hospital Schaffhausen) between 01/2019 - 04/2020 following the same study protocol. All patients were seen preoperatively in an outpatient clinic or emergency room. Patients were examined by a surgeon and anesthesiologist and after evaluation of the objective status, comorbidities and social situation, the procedure and postoperative management according to the AVOS guidelines were decided. Patients with a recurrent or bilateral hernia were excluded as they could bias the re-admission rate as the complication rate and need for analgesia are higher in these patients. The primary endpoint of the study was re-admission rate within 6 weeks postoperatively due to complication (a: seroma, b: hematoma, c: wound infection/dehiscence, d: recurrence, e: pain, f: postop. delirium). Secondary endpoints were the complication rate and patient outcome at 6 weeks postoperatively measured by the SF-36 questionnaire, a well-established tool for measuring the performance status and quality of life of patients in 8 different categories.
Intention-to-treat analysis was done and descriptive statistics using the chi-square test for categorical variables was used to measure the relationship between treatment setting and complication rate as well as treatment setting and re-admission rate. Per protocol analysis with an independent t-test was used to find any significant difference between the treatment setting and mean clinical outcome of the patients measured by SF-36 at 6 weeks postoperatively. P < 0.05 was statistically significant. The study was approved by the Ethics Committee of Zürich (Kantonale Ethikkomission Zürich, BASEC Nr. 2018-10832)
- Being tested
- inguinal hernia repair
- Keywords
- inguinal hernia treatment, AVOS, complications, re-admission, outcome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
inguinal hernia repairProcedure or surgery
inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
| Study group | Role | What they receive |
|---|---|---|
| stationary/inpatient | Not described Receives: Procedure: inguinal hernia repair | |
| ambulatory/outpatient | Not described Receives: Procedure: inguinal hernia repair |
What is being measured
The primary outcome is the main question the study is designed to answer.
re-admission rate
Measured: 6 weeks
complication rate
a: seroma, b: hematoma, c: wound infection/dehiscence, d: recurrence, e: pain, f: postop. delirium
Measured: 6 weeks
quality of life
SF-36 questionnaire
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2022
- Study start1 Jan 2019
- Primary completion1 Apr 2020
- Study completion1 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Outcome of Outpatient/Ambulatory and Inpatient/Stationary SettingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Michal Ziga
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Michal Ziga, Cantonal Hospital Schaffhausen
- Investigators
- Michal Ziga, Dr., Principal investigator, Cantonal Hospital Schaffhausen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05234242
- Sponsor's protocol ID
- HerStAmb Study
- Status last verified
- Feb 2022
- First submitted
- 1 Feb 2022
- Last updated
- 10 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Ziga M, Burla L, Imhof A, Gurtler T, Weber M. Inguinal hernia treatment in Switzerland: inpatient vs. outpatient setting - HerStAmb Study (prospective observational two-centre comparative study). Langenbecks Arch Surg. 2023 Jan 9;408(1):14. doi: 10.1007/s00423-023-02766-y.
PubMed 36622458
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inguinal Hernia Treatment: Stationary/Inpatient vs. Ambulatory/Outpatient Setting - HerStAmb Study (Prospective Non-randomized Multicenter Comparative Study)
- ClinicalTrials.gov ID
- NCT05234242
- Acronym / sponsor ID
- HerStAmb Study
- Keywords
- inguinal hernia treatment, AVOS, complications, re-admission, outcome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- Dr. Michal ZigaUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 1 Apr 2020 (actual)
- Study completion
- 1 Apr 2020 (actual)
- First posted
- 10 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since 01/2018, AVOS (ambulant vor stationär = ambulatory to stationary) regulation has been progressively implemented in hospitals across Switzerland for certain surgical procedures, including the treatment of inguinal hernias.
The aim of this prospective, non-randomized, multicenter study was to compare the outcome of outpatient/ambulatory and inpatient/stationary postoperative care by examining the re-admission rate, complication rate and quality of life in patients with primary unilateral inguinal hernia repair.
Detailed description
Inguinal hernia repair procedures are among the most performed surgeries worldwide, with more than 20 million people undergoing the procedure annually. Various tension or tension-free operation-techniques have been developed over the years. According to the International Guidelines developed by HerniaSurge Group in 2018, the gold standard are tension-free procedures with prosthetic material (mesh), either laparoscopic (total extraperitoneal patch (TEP), transabdominal preperitoneal patch (TAPP) or open surgery (Lichtenstein). In Switzerland, open surgery is used for 58.5% of hernias while 41.5% are operated on laparoscopically with the TEP as the first choice. Similar data is also reported in Great Britain. The development of modern anaesthesia as well as the safe techniques performed by experienced surgeons permit treatment of inguinal hernias in the outpatient setting, while the American Society of Anaesthesiologists (ASA) state that I - III class patients who have satisfactory care at home should be considered for day surgery. A crucial role in the process is played by the anaesthesiologist and surgeon who are responsible for perioperative management and the early postoperative phase. The factors in favour or against the suitability of day surgery include environmental factors (hospital, physician) as well as patient-related factors and thus a tailored approach must be considered for each patient. Outpatient treatment can only be performed in a hospital with suitable infrastructure (pre-assessment, day surgery department) and a high caseload, which usually results in the surgery being routine, with less complications occurring and a shorter procedure time. Control of postoperative pain and nausea are also very important for quick discharge. The financial support of the healthcare system also plays a significant role.
While there is a growing trend towards day surgery, considerable variations exist internationally and between hospitals at the national level. The evaluation of the French hernia register by Drissi et al showed slightly lower re-admission rate in ambulatory patients while Steger et al report a positive experience as well as acceptance of the ambulatory TEP procedure in one centre in Germany. Köckerling et al showed no significant differences in pain and recurrence rate in primary elective unilateral inguinal hernia treated in the outpatient setting. However, there are no prospective studies and data comparing outpatient/ambulatory vs. inpatient/stationary treatment setting in respect of complications, re-admission rate and patient outcome/quality of life.
Since 01/2018, AVOS (ambulant vor stationär = ambulatory to stationary) regulation has been progressively implemented in Swiss hospitals for certain procedures - inguinal hernia treatment included. AVOS regulation passed into law in 01/2019, with small modifications made to the recommendations of the European Hernia Society for hernia treatment in the outpatient setting.
Our study is the first prospective study comparing the efficiency and the effectiveness of ambulatory/outpatient and stationary/inpatient postoperative management through the investigation of the postoperative re-admission rate, complication rate and patient outcome/quality of life after the procedure in a group of patients with primary unilateral inguinal hernia.
The study was designed as a prospective non-randomized multicentre study carried out at 2 Swiss hospitals (Centre A: Triemli City Hospital, Centre B: Cantonal Hospital Schaffhausen) between 01/2019 - 04/2020 following the same study protocol. All patients were seen preoperatively in an outpatient clinic or emergency room. Patients were examined by a surgeon and anesthesiologist and after evaluation of the objective status, comorbidities and social situation, the procedure and postoperative management according to the AVOS guidelines were decided. Patients with a recurrent or bilateral hernia were excluded as they could bias the re-admission rate as the complication rate and need for analgesia are higher in these patients. The primary endpoint of the study was re-admission rate within 6 weeks postoperatively due to complication (a: seroma, b: hematoma, c: wound infection/dehiscence, d: recurrence, e: pain, f: postop. delirium). Secondary endpoints were the complication rate and patient outcome at 6 weeks postoperatively measured by the SF-36 questionnaire, a well-established tool for measuring the performance status and quality of life of patients in 8 different categories.
Intention-to-treat analysis was done and descriptive statistics using the chi-square test for categorical variables was used to measure the relationship between treatment setting and complication rate as well as treatment setting and re-admission rate. Per protocol analysis with an independent t-test was used to find any significant difference between the treatment setting and mean clinical outcome of the patients measured by SF-36 at 6 weeks postoperatively. P < 0.05 was statistically significant. The study was approved by the Ethics Committee of Zürich (Kantonale Ethikkomission Zürich, BASEC Nr. 2018-10832)
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| stationary/inpatient | – | Procedure: inguinal hernia repair |
| ambulatory/outpatient | – | Procedure: inguinal hernia repair |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All the patients included in the study were diagnosed with the symptomatic primary unilateral inguinal hernia. They have various jobs and different lifestyles.
Key inclusion criteria (3 listed)
- Primary unilateral inguinal hernia
- Written informed consent after participants' information,
- Outpatient or inpatient treatment
Key exclusion criteria (2 listed)
- Recurrent hernia
- Bilateral hernia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| inguinal hernia repairinguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting | Procedure or surgery | ambulatory/outpatient, stationary/inpatient |
Primary outcome
re-admission rate
Time frame: 6 weeks
complication rate
Time frame: 6 weeks
a: seroma, b: hematoma, c: wound infection/dehiscence, d: recurrence, e: pain, f: postop. delirium
quality of life
Time frame: 6 weeks
SF-36 questionnaire
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2022.
- Derived from this study: PubMed 36622458Ziga M, Burla L, Imhof A, Gurtler T, Weber M. Inguinal hernia treatment in Switzerland: inpatient vs. outpatient setting - HerStAmb Study (prospective observational two-centre comparative study). Langenbecks Arch Surg. 2023 Jan 9;408(1):14. doi: 10.1007/s00423-023-02766-y.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michal Ziga, Dr. principal investigator
Cantonal Hospital Schaffhausen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Outcome of Outpatient/Ambulatory and Inpatient/Stationary Setting, run by Dr. Michal Ziga at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
re-admission rate (time frame: 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05234242, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2022.